Imricor Medical Systems announced the first three cardiac ablation procedures were completed in the first clinical study that is evaluating the feasibility of their MR-enabled products to treat atrial flutter.

Professor Reza Razavi, Head of the Division of Imaging Sciences & Biomedical Engineering, King’s College London, is the principal investigator for the study and along with Mark O’Neill, Professor of Cardiac Electrophysiology and Consultant Cardiologist, Guy’s and St. Thomas’ NHS Trust performed the procedures. The prospective pilot study will enroll up to 15 patients at this center.

The Vision-MR Ablation Catheter and Advantage-MR EP Recorder/Stimulator System are currently being evaluated for the treatment of atrial flutter. The Vision-MR Ablation Catheter looks, feels, and functions like a conventional ablation catheter, but its patented technology makes it uniquely MR-enabled.

The Advantage-MR EP Recording/Stimulator System is also MR-enabled to avoid dangerous electromagnetic interactions with the MRI scanner and provide clear intra-cardiac electrograms and interference-free MR images. The system delivers the needed MR-enabled recording and pacing functions. Both products are used in conjunction with the iSuite image guidance platform that is provided by Philips.

"We are very excited to work with Drs. Razavi and O’Neill and the rest of their team, as well as Philips Research, to make this long awaited dream of MR-guided cardiac ablations a reality. Imricor is the world leader in developing MR-guided interventional products for electrophysiology, and this study marks a quantum step forward for the field," said Steve Wedan, Imricor’s President and Chief Executive Officer.